The influence of carbapenem resistance on mortality in solid organ transplant recipients with Acinetobacter baumannii infection

Erika Ferraz de Gouvêa, Ianick Souto Martins, Marcia Halpern, Adriana Lúcia Pires Ferreira, Samanta Teixeira Basto, Renato Torres Gonçalves, Beatriz Meurer Moreira and Guilherme Santoro-Lopes

Abstract

Background: Infection with carbapenem-resistant Acinetobacter baumannii has been associated with high morbidity and mortality in solid organ transplant recipients. The main objective of this study was to assess the influence of carbapenem resistance and other potential risk factors on the outcome of A. baumannii infection after kidney and liver transplantation.

Methods: Retrospective study of a case series of A. baumannii infection among liver and renal transplant recipients. The primary outcome was death associated with A. baumannii infection. Multivariate logistic regression was used to assess the influence of carbapenem resistance and other covariates on the outcome.

Results: Forty-nine cases of A. baumannii infection affecting 24 kidney and 25 liver transplant recipients were studied. Eighteen cases (37%) were caused by carbapenem-resistant isolates. There were 17 (35%) deaths associated with A. baumannii infection. In unadjusted analysis, liver transplantation (p = 0.003), acquisition in intensive care unit (p = 0.001), extra-urinary site of infection (p < 0.001), mechanical ventilation (p = 0.001), use of central venous catheter (p = 0.008) and presentation with septic shock (p = 0.02) were significantly related to a higher risk of mortality associated with A. baumannii infection. The number of deaths associated with A. baumannii infection was higher among patients infected with carbapenem-resistant isolates, but the difference was not significant (p = 0.28). In multivariate analysis, the risk of A. baumannii-associated mortality was higher in patients with infection acquired in the intensive care unit (odds ratio [OR] = 34.8, p = 0.01) and on mechanical ventilation (OR = 15.2, p = 0.04). Appropriate empiric antimicrobial therapy was associated with significantly lower mortality (OR = 0.04, p = 0.03), but carbapenem resistance had no impact on it (OR = 0.73, p = 0.70).

Conclusion: These findings suggest that A. baumannii-associated mortality among liver and kidney transplant recipients is influenced by baseline clinical severity and by the early start of appropriate therapy, but not by carbapenem resistance.

Keywords: Acinetobacter baumannii, Resistance, Carbapenem, Transplantation, Mortality
Background

Bacterial infections are among the most relevant causes of morbidity and mortality after organ transplantation. The high prevalence of multidrug-resistant among bacterial pathogens causing infections in solid organ transplant recipients is an additional concern [1,2]. In a recent report, infections with multidrug-resistant Gram-negative bacteria were associated with higher mortality among liver transplant recipients [3]. In this context, the emergence of carbapenem-resistant Acinetobacter baumannii (CRAB) as a significant pathogen in many transplant centers around the world is a special dilemma due to the limited therapeutic choices available to treat these infections [1,4]. Nonetheless, there are few data on the epidemiology of CRAB infection among solid organ transplant recipients and on its impact on the survival of these patients [5-9]. The objective of the present study was to analyze the possible influence of carbapenem resistance and other potential risk factors on mortality among solid organ transplant recipients with A. baumannii infection.

Methods

Study design

This was a retrospective study of a case-series of kidney transplant (KT) and liver transplant (LT) patients with infection by A. baumannii. A case-patient was defined as a subject with A. baumannii infection according to Centers of Disease Control and Prevention criteria [10]. The study was approved by the Institutional Committee on Research Ethics of the Hospital Universitário Clementino Fraga Filho/Medicine School of the Universidade Federal do Rio de Janeiro.

The primary endpoint was death associated with A. baumannii infection, and the secondary endpoint was death by any cause within 30 days of infection onset. Death was defined as associated with A. baumannii infection if the patient had persistent manifestations of the infection and no other possible cause of death was detected.

Case finding and data collection

An electronic search was performed in the microbiology database to identify potential case-patients from January 2002 to January 2009. Data on the following variables were collected from patients’ medical records: sex; age; use of antimicrobial drugs within the previous 3 months; the use of hemodialysis, mechanical ventilation and of central venous catheters at the time of A. baumannii infection diagnosis; treatment for acute graft rejection with methyl-prednisolone pulse therapy or anti-thymocyte globulin within the previous three months; date of hospital and intensive care unit (ICU) admission; site and date of diagnosis of A. baumannii infection, and the use of appropriate empiric antibiotic therapy. This was defined as the start of an effective antimicrobial drug within 48 hours after the diagnosis of infection. Anti-microbial therapy with polymyxin B was presumed to be effective for cases of CRAB infection although susceptibility test for this antibiotic was not routinely performed. The date of infection was defined as that when the first clinical specimen with isolation of A. baumannii was collected. Infection was defined as acquired in hospital or in the ICU if occurred >48h after hospital or ICU admission, respectively. All patients were followed until death or hospital discharge.

Bacterial identification and antimicrobial susceptibility testing were performed by the VITEK-1 system (BioMérieux Vitex Inc, Hazelwood, USA). Susceptibility to imipenem, gentamicin, amikacin, ampicillin/sublactam, piperacillin-tazobactam, cefotaxime, cefadizime, cefepime, ciprofloxacin, minocycline and trimethoprim/sulfamethoxazole was determined by disk-diffusion according to CLSI recommendations [11]. As of July 2006, isolates were also tested for meropenem susceptibility. Isolates with intermediate susceptibility to imipenem or meropenem were also defined as carbapenem-resistant.

Transplant protocols

Perioperative antimicrobial prophylaxis for kidney and liver transplantation consisted of cefazolin for 24 hours and ampicillin plus sublactam for 48 hours, respectively. Immediately after transplantation, KT patients remained in the nephrology unit with a basic immunosuppressive protocol consisting of a triple drug regimen including corticosteroids, a calcineurin inhibitor (usually tacrolimus) and mycophenolate moftel or sirolimus. Dual drug regimens consisting of corticosteroids and mycophenolate moftel or tacrolimus were prescribed for recipients of allografts from HLA-identical donors. Anti-thymocyte globulin was used as induction therapy in KT patients who underwent retransplantation.

After transplantation, LT patients were admitted to a surgical ICU where they remained until weaned from mechanical ventilation. Immunosuppression for LT patients with chronic hepatitis B or C infection consisted of corticosteroids and a calcineurin inhibitor (tacrolimus or cyclosporin). Azathioprine or mycophenolate was additionally used for the immunosuppression of patients with other indications for LT.

For both LT and KT patients, trimethoprim/sulfamethoxazole (80mg/400mg per day) was prescribed for six months to one year after transplantation to prevent Pneumocystis jiroveci infection.

Statistical analysis

The Mann–Whitney test was used to compare the distribution of numeric variables while the Chi-square and
Fisher's exact tests were used to analyze categorical variables. Potential associations of the study variables with the outcomes were explored by univariate and multivariate analyses in logistic regression models. All covariates that were associated with a p value <0.25 in the univariate analysis were selected for the multivariate analysis. Final adjusted models were obtained with a forward stepwise regression approach. Due to its clinical relevance, the variable “carbapenem resistance” was selected for the multivariate analysis and retained in all models analyzed in the stepwise regression process. Other variables were added one by one. The selection of the variable to be included at each additional step was based on their p value calculated with the log-likelihood ratio test. Only variables associated with a p-value ≤0.10 were included in the model. Variables with a p-value >0.10 were removed from the adjusted models. Collinearity between variables was checked. The goodness of fit of the final adjusted models was assessed by the Hosmer-Lemeshow test. Additionally, the Akaike’s information criterion (AIC) was used to compare candidate multivariable models. The selected final adjusted model for each studied outcome was that with the lowest AIC. To analyze the discrimination of the adjusted models for the prediction of each outcome we calculated the area under the receiver-operating curve (ROC) that were plotted using the predicted values and observed events. All p values presented are bicaudate and a p < 0.05 was considered statistically significant. Statistical analyses were performed with SPSS for Windows 18.0 (SPSS Inc., Chicago, Illinois).

Table 1: Distribution of the study variables in kidney transplant and liver transplant recipients with *Acinetobacter baumannii* infection

| Variable                        | Liver transplant (total = 25) | Kidney transplant (total = 24) | p   |
|---------------------------------|-------------------------------|--------------------------------|-----|
| Male sex                        | 16 (64)                       | 13 (54)                        | 0.48|
| Agea                            | 56 (38–63)                    | 44 (31–55)                     | 0.09|
| Infection acquired in the ICU   | 22 (88)                       | 2 (8)                          | <0.001|
| Previous use of any antibioticb | 11 (55)                       | 11 (55)                        | 1.0 |
| Previous use of carbapenem b    | 8 (40)                        | 3 (15)                         | 0.08|
| Non-urinary site of infection   | 24 (96)                       | 11 (46)                        | <0.001|
| Primary bacteremia              | 9 (36)                        | 8 (33)                         |     |
| Pneumonia                       | 11 (44)                       | 2 (18)                         |     |
| Surgical site infection         | 4 (16)                        | 1 (4)                          |     |
| Bacteremia c                    | 16 (64)                       | 12 (50)                        | 0.32|
| Central venous catheter         | 25 (100)                      | 6 (25)                         | <0.001|
| Mechanical ventilation          | 21 (84)                       | 4 (17)                         | <0.001|
| Serum creatinine (μmol/L) a     | 130 (90 – 200)                | 320 (120–500)                  | 0.009|
| Hemodialysis                    | 8 (32)                        | 4 (17)                         | 0.21|
| Treated for acute graft rejection| 1 (4)                         | 11 (46)                        | 0.001|
| Septic shock                    | 11 (44)                       | 4 (17)                         | 0.04|
| Appropriate empiric therapy for *A. baumannii* infection | 17 (68) | 12 (50) | 0.20|
| Resistance to carbapenem        | 12 (48)                       | 6 (33)                         | 0.10|

ICU – intensive care unit; a median (interquartile range); b Data available in 40 patients; c includes 11 cases of secondary bacteremia.

Results

During the study, 800 subjects underwent kidney (562 patients) or liver transplantation (238 patients). *A. baumannii* infection was diagnosed in 49 patients (6.1%). The cumulative incidence was significantly higher among LT recipients (25 cases, 10.5%) than in KT recipients (24 cases, 4.3%, p < 0.001). The sites of infection included 17 blood stream infections (4 related to central venous catheter), 14 symptomatic urinary tract infections, 13 pneumonias (10 associated with mechanical ventilation), 5 surgical site infections (one superficial and 4 intra-abdominal). The median time from transplantation to the diagnosis of *A. baumannii* infection was not significantly different between LT (13 days, interquartile range [IQR]: 6–45 days) and KT (13.5 days, IQR: 7–137 days) recipients (p = 0.23). KT and LT subjects affected by *A. baumannii* infection differed significantly regarding several other aspects (Table 1). LT recipients presented a higher frequency of infections acquired in the ICU (p < 0.001), affecting a non-urinary site (p < 0.001) and associated with septic shock (p = 0.04), mechanical ventilation (p < 0.001) and central venous catheter use (p < 0.001). In addition, LT patients tended to be older (p=0.09) and to have a more frequent history of
previous carbapenem therapy (p = 0.08). On the other hand, treatment for an acute rejection episode was more frequent among KT recipients (p < 0.001). These patients also had a significantly higher serum creatinine level (p = 0.009).

Eighteen infections (37%) were caused by CRAB. Susceptibility tests for meropenem were available in eight of these cases. Resistance to both imipenem and meropenem was observed in all of them. The median time after transplantation to the diagnosis of the infection was longer for CRAB (20 days, IQR: 9–299 days) than for carbapenem susceptible A. baumannii infections (9 days; IQR: 5–27 days). The proportion of infections caused by CRAB was higher among LT recipients, but the difference was not statistically significant (p = 0.10, Table 1).

Table 2 presents the distribution of other variables between cases of CRAB and carbapenem susceptible A. baumannii infection. CRAB infections were significantly associated with previous use of any antibiotic (p = 0.001) and, specifically, carbapenem (p < 0.001). CRAB infections were also significantly more frequent in patients with use of central venous catheter (p = 0.005) and in subjects undergoing hemodialysis (p = 0.01).

A total of 19 (39%) patients died: 18 within 30 days, and one on the 52nd day after the diagnosis of the infection. This was the case of a liver transplant recipient who was reoperated on the first postoperative week because of a biliary fistula that was successfully repaired with a choledochojunostomy. On the 28th postoperative day, she was reoperated due to an abdominal abscess caused by Stenotrophomonas maltophilia. On the 50th postoperative day she was reoperated again to drain another abdominal abscess. CRAB was isolated in the clinical specimen collected during this surgery. Despite prolonged treatment with polymyxin B combined with meropenem, she underwent laparotomy in two other occasions due to the persistence of the abdominal infection. CRAB was still isolated from the abscess secretion collected during the last reoperation, which took place one week before her death.

In 17 cases (35%), deaths were defined as associated with A. baumannii infection, including the one occurring 52 days after the infection. Most A. baumannii-associated deaths (15 cases, 88%) occurred within 14 days of the diagnosis. The median time from the diagnosis of infection to death tended to be shorter among patients who did not receive appropriate empiric antimicrobial therapy (one day) than in other patients (8 days, p = 0.07).

In unadjusted logistic regression analyses (Table 3), liver transplantation (p = 0.003), acquisition in ICU (p = 0.001), extra-urinary site of infection (p < 0.001), mechanical ventilation (p = 0.001), use of central venous catheter (p = 0.008) and presentation with septic shock (p = 0.02) were significantly related to a higher risk of mortality associated with A. baumannii infection.

### Table 2 Distribution of the study variables in patients with carbapenem resistant and carbapenem susceptible Acinetobacter baumannii infections

| Variable                                      | Carbapenem-Resistant (total = 18) | Carbapenem-Susceptible (total = 31) | p     |
|-----------------------------------------------|-----------------------------------|-------------------------------------|-------|
| Male sex                                      | 8 (44)                            | 21 (68)                             | 0.11  |
| Agea                                          | 48 (28–63)                        | 48 (37–58)                         | 0.94  |
| Infection acquired in the ICU                 | 11 (61)                           | 13 (42)                             | 0.20  |
| Previous use of any antibioticb               | 14 (88)                           | 8 (33)                              | <0.001|
| Previous use of carbapenem b                  | 10 (63)                           | 1 (4)                               | 0.001 |
| Non-urinary site of infection                 | 14 (78)                           | 21 (68)                             | 0.45  |
| Primary bacteremia                            | 5 (28)                            | 12 (39)                             |       |
| Pneumonia                                     | 6 (33)                            | 7 (23)                              |       |
| Surgical site infection                       | 3 (17)                            | 2 (6)                               |       |
| Bacteremia c                                  | 9 (50)                            | 19 (61)                             | 0.44  |
| Central venous catheter                       | 16 (89)                           | 15 (48)                             | 0.005 |
| Mechanical ventilation                        | 12 (67)                           | 13 (42)                             | 0.10  |
| Serum creatinine (μmol/L) a                   | 200 (110 – 290)                   | 230 (110–460)                       | 0.39  |
| Hemodialysis                                  | 8 (44)                            | 4 (13)                              | 0.01  |
| Therapy for acute graft rejection             | 2 (11)                            | 10 (32)                             | 0.10  |
| Septic shock                                  | 8 (44)                            | 7 (23)                              | 0.11  |
| Appropriate empiric therapy for A. baumannii infection | 10 (56) | 19 (61) | 0.69  |

ICU – intensive care unit; a median(interquartile range); b data available in 40 patients; c includes 11 cases of secondary bacteremia.
The number of deaths associated with *A. baumannii* infection was higher among patients infected with CRAB, but the difference was not significant (p = 0.28). Unexpectedly, therapy for acute graft rejection was associated with lower mortality (p = 0.03). This finding probably reflects confounding, as acute rejection was diagnosed more frequently among KT recipients who presented with lower baseline clinical severity as compared with LT recipients. Univariate regression analyses with overall 30-day mortality as the outcome yielded similar results (Table 4).

In multivariate analyses (Table 5), ICU-acquired infection (p = 0.01) and mechanical ventilation at baseline (p = 0.04) were significantly related to a higher risk of death associated with *A. baumannii* infection. Oppositely, appropriate empiric antimicrobial therapy was associated with a significantly lower *A. baumannii*-associated mortality (p = 0.03). Acquisition in the ICU was the only factor significantly related to overall 30-day mortality (p = 0.001). In both multivariate analyses, resistance to carbapenem had no impact on mortality. The exclusion of resistance to carbapenem from the multivariate analysis did not cause appreciable changes in the results of the final adjusted model for each outcome (data not shown). The discrimination of the final multivariate model to predict death associated with *Acinetobacter baumannii* infection, as estimated by the area under the ROC curve, was 0.901 (95% confidence interval [CI]: 0.781 to 0.968). The area under the ROC curve calculated for the adjusted model for overall 30-day mortality was 0.799 (95% CI: 0.667 to 0.931).

### Discussion

The emergence of infections caused by CRAB and other multi-drug resistant bacteria among transplant patients poses a difficult therapeutic challenge. In CRAB infections, therapeutic options are frequently restricted to drugs such as polymyxins and amikacin, which are associated with a higher risk of toxicity. Tigecycline has a better toxicity profile, however, its use as a monotherapy for the treatment of severe infections caused by CRAB, such as bacteremia and hospital-acquired pneumonia, is considered clinically unreliable [1,12]. Such therapeutic limitations justify the hypothesis that CRAB infection might be associated with a poorer prognosis especially in immunocompromised hosts.

Most studies that addressed the impact of *A. baumannii* infection on mortality defined overall 14 or 30-day mortality as their primary outcome. However, it has been observed both in transplant recipients [8] and in other critically ill patients [13] that CRAB infection may have a prolonged course that may ultimately result in death after several weeks of continued antimicrobial therapy [8]. Thus, the analysis of overall 14-day mortality might underestimate the impact of CRAB on mortality. On the other hand, overall 30-day mortality is more

### Table 3 Univariate analyses of risk factors for death associated with *Acinetobacter baumannii* infection

| Variable | Deaths (n = 17) | Survivors (n = 32) | Odds ratio (95% CI) | P  |
|----------|----------------|-------------------|---------------------|----|
| Male sex | 9 (53)         | 20 (63)           | 0.68 (0.21 – 2.22)  | 0.52 |
| Age (each 10 years) | 10 (59) | 12 (38) | 1.08 (0.74 – 1.55) | 0.70 |
| Liver transplant | 14 (82) | 11 (34) | 8.91 (2.10 – 37.8) | 0.003 |
| Infection acquired in the ICU | 15 (88) | 9 (28) | 19.2 (3.63 – 101.3) | 0.001 |
| Previous use of any antibiotic | 5 (36) | 17 (65) | 0.29 (0.08 – 1.15) | 0.08 |
| Previous use of carbapenem | 4 (29) | 7 (27) | 1.09 (0.26 – 4.62) | 0.91 |
| Extra-urinary site of infection | 17 (100) | 18 (56) | Undefined | <0.001 |
| Primary bacteremia | 7 (41) | 10 (31) | | |
| Pneumonia | 7 (41) | 6 (19) | | |
| Surgical site infection | 3 (18) | 2 (6) | | |
| Bacteremia | 11 (65) | 17 (53) | 1.43 (0.42 – 4.81) | 0.57 |
| Central venous catheter | 16 (94) | 15 (47) | 18.1 (2.14 – 153.6) | 0.008 |
| Mechanical ventilation | 15 (88) | 10 (31) | 16.5 (3.16 – 86.3) | 0.001 |
| Serum creatinine (for each 100 μmol/L) | 170 (80–230) | 270 (110–460) | 0.68 (0.44 – 1.06) | 0.10 |
| Hemodialysis | 6 (35) | 6 (19) | 2.36 (0.62 – 8.97) | 0.21 |
| Therapy for acute graft rejection | 1 (6) | 11 (34) | 0.17 (0.03 – 0.88) | 0.03 |
| Septic shock | 9 (53) | 6 (19) | 4.88 (1.33 – 17.9) | 0.02 |
| Appropriate empiric therapy | 8 (47) | 21 (66) | 0.47 (0.14 – 1.55) | 0.21 |
| Resistance to carbapenem | 8 (47) | 10 (30) | 1.96 (0.58 – 6.56) | 0.28 |

ICU = intensive care unit; CI = confidence interval; * Data available for 40 cases; † includes 11 cases of secondary bacteremia; ‡ median(interquartile range).
likely to be influenced by factors other than CRAB infection, like those related to the underlying clinical severity of the affected patients. Therefore, death associated with *A. baumannii* was defined as the primary outcome of this study. As expected, most *A. baumannii*-associated deaths occurred within 14 days. However, some patients had more prolonged course of the disease, and in one of these cases *A. baumannii*-associated death occurred 52 days after the diagnosis of infection.

There was no significant association between carbapenem resistance and mortality. It might be argued that this study was underpowered to detect a moderate increase in CRAB associated mortality. In fact, there was a non-significant increase in mortality among patients with CRAB infection in the univariate analyses. However, in the final multivariable model for death associated with *A. baumannii* infection, the estimated odds ratio for carbapenem resistance was lower than one. This finding suggests that the lack of association between carbapenem resistance and mortality in this report is unlikely to be related to inadequate statistical power. Conflicting results have been reported regarding the possible influence of carbapenem resistance on mortality among critically ill patients [14-19]. The reasons for this inconsistency are not clear, but it is probable that it comes from methodological differences among these studies, especially in the approach to minimize confounding by baseline clinical severity and to assess the effect of early appropriate therapy [19].

Acquisition of infection in the ICU and being on mechanical ventilation at the time of infection diagnosis were both strongly related to *A. baumannii*-associated death. These factors are probably surrogate markers of clinical severity and its association with mortality is in line with the results of other studies that pointed out the influence of factors related to baseline clinical severity on the outcome of *A. baumannii* infections [13,14,17,20,21].

The beneficial impact of early start of effective therapy on the outcome *A. baumannii* infection has been

---

### Table 4 Univariate analyses of risk factors for overall 30-day mortality

| Variable                              | Deaths (n = 18) | Survivors (n = 31) | Odds ratio (95% CI) | p     |
|---------------------------------------|----------------|-------------------|---------------------|-------|
| Male sex                              | 10 (56)        | 19 (61)           | 0.79 (0.24 – 2.56)  | 0.69  |
| Age (each 10 years)                   | 10 (56)        | 12 (39)           | 0.97 (0.68 – 1.38)  | 0.85  |
| Liver transplant                      | 15 (83)        | 10 (32)           | 10.5 (2.46 – 44.8)  | 0.001 |
| Infection acquired in the ICU         | 16 (89)        | 8 (26)            | 12.2 (2.83 – 52.7)  | 0.001 |
| Previous use of any antibiotic &     | 6 (40)         | 16 (64)           | 0.38 (0.10 – 1.40)  | 0.14  |
| Previous use of carbapenem            | 5 (33)         | 6 (24)            | 1.58 (0.39 – 6.50)  | 0.52  |
| Extra-urinary site of infection       | 17 (94)        | 18 (58)           | 12.4 (1.45 – 100.0) | 0.02  |
| Primary bacteremia                    | 7 (39)         | 10 (32)           |                     |       |
| Pneumonia                             | 8 (44)         | 5 (16)            |                     |       |
| Surgical site infection               | 2 (11)         | 3 (10)            |                     |       |
| Bacteremia b                          | 12 (67)        | 16 (52)           | 1.65 (0.49 – 5.52)  | 0.42  |
| Central venous catheter               | 17 (94)        | 14 (45)           | 20.6 (2.44 – 175.0) | 0.005 |
| Mechanical ventilation                | 15 (83)        | 10 (32)           | 10.5 (2.46 – 44.8)  | 0.001 |
| Serum creatinine (for each 100 μmol/L) | 200 (100 – 250) | 220 (110 – 460)   | 0.76 (0.52 – 1.11)  | 0.16  |
| Hemodialysis                          | 7 (39)         | 5 (17)            | 3.31 (0.86 – 12.7)  | 0.08  |
| Therapy for acute rejection           | 2 (11)         | 10 (32)           | 0.28 (0.07 – 1.16)  | 0.08  |
| Septic shock                          | 10 (56)        | 5 (16)            | 4.17 (1.15 – 15.0)  | 0.03  |
| Appropriate empiric therapy           | 11 (50)        | 18 (58)           | 0.79 (0.24 – 2.56)  | 0.69  |
| Resistance to carbapenem              | 9 (50)         | 9 (29)            | 2.44 (0.73 – 8.17)  | 0.15  |

ICU – intensive care unit; CI = confidence interval; * Data available for 40 cases; ** includes 11 cases of secondary bacteremia; † median(interquartile range).

---

### Table 5 Variables associated with mortality among liver and kidney transplant recipients with *A. baumannii* infection in multivariate logistic regression analysis

| Models                          | Odds ratio (95% CI) | p     |
|--------------------------------|---------------------|-------|
| **A. baumannii-associated mortality** |                     |       |
| Infection acquired in the ICU    | 34.8 (2.05 – 593.1) | 0.01  |
| Mechanical ventilation           | 15.2 (1.22 – 189.2) | 0.04  |
| Appropriate empiric therapy      | 0.04 (0.002 – 0.74) | 0.03  |
| Resistance to carbapenem         | 0.73 (0.12 – 4.47)  | 0.70  |
| **Overall 30- day mortality**    |                     |       |
| Infection acquired in the ICU    | 11.5 (2.61 – 49.8)  | 0.001 |
| Resistance to carbapenem         | 1.93 (0.48 – 7.85)  | 0.36  |

CI: confidence interval; ICU: intensive care unit.

---

Gouvêa et al. BMC Infectious Diseases 2012, 12:351
http://www.biomedcentral.com/1471-2334/12/351

---

Gouvêa et al. BMC Infectious Diseases 2012, 12:351
http://www.biomedcentral.com/1471-2334/12/351
suggested by the results of other studies [6,18-22]. Indeed, Kwon at al. observed that carbapenem resistance was related to mortality in patients with *A. baumannii* bacteremia only if the use of effective therapy was not taken into account in the analysis [19]. Accordingly, in this series of abdominal organ transplant recipients, the use of appropriate empiric antimicrobial therapy was related to a significantly better outcome. Similar results have been reported by Kim and cols. [6] in a small case series of living-donor liver transplant recipients. However, that study also included subjects infected with *Acinetobacter lwoffii*, a species that has been associated with low mortality in immunocompromised patients [23]. It is plausible that the impact of delaying appropriate antimicrobial therapy for these infections may be higher in immunocompromised hosts than in immunocompetent patients. However, this issue was not addressed in the present study. Similarly to what has been described elsewhere [6,18,19,21,22], the proportion of patients who received inappropriate empirical antibiotic therapy was high in this series. Our findings underscore the importance of finely adjusting the selection of empiric antimicrobial therapy to the local epidemiological conditions.

The epidemiology and outcome of *A. baumannii* infection among KT recipients is largely unknown. We found that the overall cumulative incidence of *A. baumannii* infection was significantly lower in KT recipients than in LT patients. The prevalence of carbapenem resistance was not significantly different between isolates from both groups of patients, but clinical severity at the time of infection diagnosis was lower among KT patients as indicated by significantly lower frequency of ICU-acquired infection, use of central venous catheter, mechanical ventilation and extra-urinary site infection. As expected, the diagnosis of acute graft rejection was more frequent among KT recipients, but this factor was not independently related to *A. baumannii*-associated mortality in our analyses. The lower baseline clinical severity was probably responsible for the better outcome of KT patients that was observed only in the unadjusted statistical analysis. Unfortunately, because of the relatively small number of cases included in the study, we could not address specific prognostic factors for KT and LT recipients infected with CRAB.

The present study has some limitations. The sample size was relatively small and, thus, it is possible that the influence of some of the studied variables on mortality was missed in the multivariable analyses. Due to a retrospective design, we were not able to categorize patients according to any validated severity of illness score. Although other surrogate markers were used, we cannot rule out the possibility of residual confounding related to differences in baseline clinical severity. Similarly, it is not possible to preclude confounding by aspects related to antimicrobial therapy that were not addressed in the present study, such as the specific drug or combination of drugs used, doses and the exact number of hours elapsed between the clinical diagnosis of infection and the start of antibiotic treatment. One additional limitation of the study was the identification of *Acinetobacter* isolates by Vitek-1 system. However, most of the isolates would be classified as *A. baumannii* by the current, more accurate methods, and most human infections are caused by this species. Therefore, it is likely that this limitation did not have a major impact in the final results. Finally, because this is a single center study, the external validity of findings is uncertain. Larger, multicenter, prospective studies would help to provide a better definition of the factors that influence the outcome of *A. baumannii* infections in transplant recipients.

### Conclusions

These results suggest that *A. baumannii*-associated mortality among liver and kidney transplant recipients is influenced by baseline clinical severity and by the early start of appropriate therapy, but not by carbapenem resistance.

### Abbreviations

CRAB: Carbapenem-resistant *Acinetobacter baumannii*; KT: Kidney transplant; LT: Liver transplant; AIC: Akaike’s information criterion; ROC: Receiver operating curve; ICU: Intensive care unit; IQR: Interquartile range.

### Competing interests

The authors have no conflicts of interest to declare.

### Authors’ contributions

EFG, BMM and GSL designed the study and drafted the manuscript; ALPF carried out the microbiologic analysis; STB, MH and RTG were responsible for clinical data collection and helped to draft the manuscript; ISM in association with GSL performed data analysis. All authors read and approved the final manuscript.

### Author details

1. Infectious Disease Clinic, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rua Justino da Rocha 201/302, Vila Isabel, CEP 20551-010, Rio de Janeiro, RJ, Brazil. 2. Medicine School, Infectious Disease Section, Universidade Federal Fluminense, Rio de Janeiro, Brazil. 3. Clinical Microbiology Laboratory, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 4. Hepatology Clinic, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 5. Nephrology Clinic, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 6. Microbiology Institute, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Received: 1 June 2012 Accepted: 10 December 2012 Published: 13 December 2012

### References

1. Patel G, Perez F, Bonomo RA: Carbapenem-resistant *Enterobacteriaceae* and *Acinetobacter baumannii*: assessing their impact on organ transplantation. *Curr Opin Organ Transplant* 2010, 15:676–682.

2. Linares L, Garcia-Goez JF, Cervera C, Almela M, Sanclemente G, Cofan F, Ricart MJ, Navasa M, Moreno A: Early bacteremia after solid organ transplantation. *Transplant Proc* 2009, 41:2262–2264.
3. Shi SH, Kong HS, Xu J, Zhang WJ, Jia CK, Wang WL, Shen Y, Zhang M, Zheng SS: Multidrug resistant gram-negative bacilli as predominant bactereemic pathogens in liver transplant recipients. Transpl Infect Dis 2009, 11:405–412.

4. Michalopoulous A, Falagas ME, Karatza DC, Alexandropoulou P, Papadakis E, Gregoris L, Chalevaidis G, Pappas G: Epidemiologic, clinical characteristics, and risk factors for adverse outcome in multiresistant gram-negative primary bacteraemia of critically ill patients. Am J Infect Control 2010, 39:396–400.

5. Shields RK, Kwak EJ, Potoski BA, Doi Y, Adams-Haduch JM, Silviera FP, Toyoda Y, Pilewski JM, Crespo M, Pasculie AW, Clancy CJ, Nguyen MH: High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis 2011, 70:246–252.

6. Kim YJ, Yoon JH, Kim SI, Hong KW, Kim JI, Choi JY, Yoon SK, You YK, Lee MD, Moon IS, Kim DG, Kang MW: High mortality associated with Acinetobacter species infection in liver transplant patients. Transplant Proc 2011, 43:2397–2399.

7. Reddy P, Zembower TR, Ison MG, Baker TA, Stosor V: Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation. Transpl Infect Dis 2010, 12:87–93.

8. Nunley DR, Bauldoff GS, Mangino JE, Pope-Harman AL: Mortality Associated with Acinetobacter baumannii Infections Experienced by Lung Transplant Recipients. Lung 2010, 188:381–385.

9. Trotter V, Nami A, Pott D, Nwauhyid Z, Manning R, Martos AC Jr, Dunham MB, Shulman CI, Mckenny MG: Outcomes of Acinetobacter baumannii infection in critically ill surgical patients. Surg Infect (Larchmt) 2007, 8:437–443.

10. Horan TC, Andrus M, Dudeck MA: CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309–332.

11. CLSI: Performance Standards for Antimicrobial Susceptibility Tests: Nineteenth Informational Supplement. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute 2009, M100-S19: 46–49.

12. Michalopoulous A, Falagas ME: Treatment of Acinetobacter infections. Expert Opin Pharmacother 2010, 11:779–788.

13. Munoz-Price LS, Zembower T, Penugonda S, Schreckenberger P, Lavins MA, Weibl S, Vais D, Bajg M, Mohapatra S, Quinn JP, Weinstein RA: Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak. Infect Control Hosp Epidemiol 2010, 31:1057–1062.

14. Sheng WH, Liao CH, Lauderdale TL, Ko WC, Chen YS, Liu JW, Lau YJ, Wang LH, Liu KS, Tsai TY, Lin SY, Hsu MS, Hsu LY, Chang SC: A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis 2010, 14:e764–e769.

15. Routi C, Pratikaki M, Platsooua E, Sotiropoulou C, Nanas S, Markaki V, Vrettou C, Panari O, Giamarellou H, Rousos C: Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteraemia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 2010, 38:173–180.

16. Katsaragakis S, Markogiannakis H, Samara E, Pachylaki N, Theodoraki EM, Xanthaki A, Toutouza M, Toutouzas KG, Theodorou D: Predictors of mortality of Acinetobacter baumannii infections: A 2-year prospective study in a Greek surgical intensive care unit. Am J Infect Control 2010, 38:631–635.

17. Metan G, Sariguel F, Sumerkan B: Factors influencing survival in patients with multidrug-resistant Acinetobacter bacteraemia. Eur J Intern Med 2009, 20:540–544.

18. Jamulitrat S, Arunpan P, Phainuphong P: Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection. J Med Assoc Thai 2009, 92:413–419.

19. Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, Shin SY, Ko KS, Peck KR, Lee NY: Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007, 59:525–530.

20. Prates CG, Martins AF, Superti SV, Lopes FS, Ramos F, Cantarelli W, Zavascki AP: Risk factors for 30-day mortality in patients with carbapenem-resistant Acinetobacter baumannii during an outbreak in an intensive care unit. Epidemiol Infect 2011, 139:411–418.

21. Erbay A, Idil A, Gozel MG, Mumcuoglu I, Balaban N: Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 2009, 34(Suppl 5):S75–S79.

22. Chang DH, Wang CC, Kuo HY, Chen HP, Chen TL, Wang FD, Cho WL, Liu CY: Risk factors for mortality in patients with Acinetobacter baumannii bloodstream infection with genotypic species identification. J Microbiol Immunol Infect 2008, 41:397–402.

23. Ku SC, Hsuhe PR, Yang PC, Luh KT: Clinical and microbiological characteristics of bacteremia caused by Acinetobacter lwoffii. Eur J Clin Microbiol Infect Dis 2000, 19:501–505.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CaSS, Scopus and Google Scholar
- Research which is freely available for redistribution

Visit www.biomedcentral.com/submit